Literature DB >> 2417419

WHO Expert Committee on Biological Standardization. Thirty-fifth report.

.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 2417419

Source DB:  PubMed          Journal:  World Health Organ Tech Rep Ser        ISSN： 0512-3054


× No keyword cloud information.
  7 in total

1.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

2.  Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis.

Authors:  Paul I Creeke; Rachel A Farrell
Journal:  Ther Adv Neurol Disord       Date:  2013-01       Impact factor: 6.570

3.  Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.

Authors:  Carlos López-Gómez; Almudena Pino-Ángeles; Teresa Órpez-Zafra; María Jesús Pinto-Medel; Begoña Oliver-Martos; Jesús Ortega-Pinazo; Carlos Arnáiz; Cristina Guijarro-Castro; Jezabel Varadé; Roberto Álvarez-Lafuente; Elena Urcelay; Francisca Sánchez-Jiménez; Óscar Fernández; Laura Leyva
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

4.  SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

Authors:  Christian P Kamm; Heinrich P Mattle
Journal:  Trials       Date:  2009-12-14       Impact factor: 2.279

5.  Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial.

Authors:  Christian Philipp Kamm; Marwan El-Koussy; Sebastian Humpert; Oliver Findling; Ferdinand von Bredow; Yuliya Burren; Guido Schwegler; Dagmar Schött; Filippo Donati; Martin Müller; Norbert Goebels; Felix Müller; Johannes Slotboom; Barbara Tettenborn; Ludwig Kappos; Yvonne Naegelin; Heinrich Paul Mattle
Journal:  J Neurol       Date:  2012-05-09       Impact factor: 4.849

6.  A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge.

Authors:  Xiaohui Liu; Youtian Yang; Zhaojin Sun; Jing Chen; Jun Ai; Can Dun; Zhen F Fu; Xuefeng Niu; Xiaofeng Guo
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

7.  Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial.

Authors:  Christian P Kamm; Marwan El-Koussy; Sebastian Humpert; Oliver Findling; Yuliya Burren; Guido Schwegler; Filippo Donati; Martin Müller; Felix Müller; Johannes Slotboom; Ludwig Kappos; Yvonne Naegelin; Heinrich P Mattle
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.